
Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, Illinois, by the end of …

Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss firm Novartis in a deal …

With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger merger was announced as US …

Japanese firm Takeda Pharmaceuticals has successfully completed its acquisition of Shire Plc. The long anticipated deal has propelled the firm …

Japanese firm Takeda have gained shareholders’ approval for the $62 billion acquisition of the Irish headquartered company Shire Plc. The …

Shire has announced that it has secured European approval for its subcutaneous injection Takhzyro (lanadelumab) for the routine prevention of …
Japanese multinational Takeda is set to shut down its US headquarters in Deerfield, Illinois following the final stages of its …

Shire has completed the sale of its oncology franchise to French firm Servier for $2.4 billion, handing over the global …

It’s one of the biggest acquisitions the industry has seen at a total value of $63 billion and after weeks …

A small group of Takeda shareholders have started making a lot of noise over its $62 billion deal for Shire, …

Hemlibra was widely expected to become the dominant therapeutic for treating haemophilia patients and its latest clinical trial results only …

After posting its financials from 2017 and its guidance for the year to come, it’s clear to see why Takeda …

It’s been a week in which one of the largest pharmaceutical takeovers in history took place and yet it’s not …

After more than a month of uncertainty, Takeda has finally confirmed it has managed to successfully acquire Shire, agreeing on …

It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …